Somewhere in a laboratory, in a dish the size of a coffee cup, red blood cells are being grown from stem cells, no donor’s arm, no needle, no camp. It sounds like the end of blood donation. It isn’t, and understanding why is a useful lesson in how medical science actually moves: real progress, genuine promise, and a very long road.
Growing blood in a dish
The science is genuinely elegant. Blood cells are born in bone marrow from stem cells, so researchers take stem cells and coax them, with carefully chosen growth factors, down the pathway that produces red cells. Mature red cells are unusual cells, they have no nucleus, which is why they are so good at their single job of carrying haemoglobin, and in culture, stem-cell-derived precursors can multiply into large numbers of young red cells before they are harvested. In principle, a small sample of stem cells could yield red cells many times over, because the cells expand in a way an adult donor’s marrow never could.
Small trials, real signals
This is not purely theoretical. Small early trials have been reported, most notably in the UK around 2022, when researchers transfused minuscule amounts of lab-grown red cells into volunteers to see whether the cells survived normally in the bloodstream. The results were encouraging enough to keep the field alive and funded. But notice the scale of what happened: tiny volumes, a handful of participants, and a question as basic as “do the cells survive?” That is the honest state of play, a proof of concept, not a product.
The promise
Why bother? Three reasons, and they are good ones. First, rare groups: patients with uncommon blood types are hard to match from ordinary donations, and lab-grown cells could, in principle, be tailored to match. Second, chronic transfusion: people with thalassaemia or sickle cell disease receive transfusions for life and slowly develop antibodies against donor cells; cells grown from a single well-matched source could ease that burden. Third, expiry: lab-grown cells wouldn’t consume perishable donated stock, they could, in principle, be made when needed rather than competing with the inventory clock that governs every donated unit.
The reality
Now the arithmetic, which is where the dream meets the spreadsheet. Growing red cells at laboratory scale is staggeringly expensive, the cost of producing one standard unit in today’s conditions is astronomical, orders of magnitude beyond any health system. The volumes produced in experiments are tiny, a fraction of what a single routine donation yields. Scaling up means industrial bioreactors, consistent quality control, regulatory approval, and a price curve that has to fall by factors that are hard to comprehend, and none of those steps is solved. Even optimistic researchers talk in terms of niche uses for the most difficult patients long before any general replacement. This is experimental science, and it will remain so for the foreseeable future.
Donors remain the only real supply
Here is the sentence that matters, and we will write it plainly: lab-grown red cells do not exist as a supply, and patients are not waiting on them, they are waiting on donors. Every unit transfused in Assam today, tomorrow and for years to come comes from a person. The laboratory work is exciting precisely because it may one day help the hardest-to-match patients, but “one day” does not help a mother bleeding tonight. Donors remain irreplaceable today, and the register that finds them is the most advanced blood technology in actual use.
Follow the wider research in can blood be manufactured and artificial oxygen carriers, or ground yourself in what blood actually is. Then do what no dish can do yet: register as a donor.